These findings are in line with previous studies showing that the expression of acylcarnitine metabolism-related genes are altered in NASH-driven HCC mouse models, including HFD-fed major urinary protein (MUP)- urokinase-type plasminogen activator (uPA) [190] mice and phosphatidylinositol 3-kinase catalytic subunit alpha PI3KCA transgenic mice [191]. Here, PLAU is linked to metabolic dysfunction-associated steatohepatitis.